A large retrospective cohort study from 5 international melanoma centers reported that the median overall survival of advanced melanoma patients after resistance to BRAF inhibitors was only 2.9 months,[2] highlighting an urgent and unmet medical need for more effective targeted therapeutics. This evidence concerns the gene BRAF and melanoma.